Hepatic Enzyme Profiles Before and after Antiretroviral Therapy among HIV-Seropositive Patients at Ebonyi State University Teaching Hospital: A Comparative Study
Okoi Benedette Leko
Department of Medical Laboratory Science, Federal University of Health Sciences, Along Ora Road, Ila Orangun, Osun State, Nigeria.
Mudathir Qossim *
Department of Medical Microbiology, Abubakar Tafawa Balewa University, Bauchi, Nigeria.
Yusuf Ahmed
Department of Medical Laboratory Science, Federal University of Health Sciences, Along Ora Road, Ila Orangun, Osun State, Nigeria.
Oniye Adesola Helen
Faculty of Medical Laboratory Science, Lead City' University, Ibadan, Oyo Statae, Nigeria.
Adetokunbo Ajala
Department of Chemical Pathology, Federal University of Health Sciences, Ila-Orangun, Osun State, Nigeria.
Sambo Justice Ede
Department of Pharmacology College of Medical Sciences Abubakar Tafawa Balewa University, Bauchi, Nigeria.
*Author to whom correspondence should be addressed.
Abstract
Background: Human immunodeficiency virus (HIV) infection and antiretroviral therapy (ART) may be associated with changes in liver-associated biochemical markers. Evaluating these markers is important for monitoring the health of people living with HIV and identifying potential biochemical abnormalities.
Aim: This study assessed and compared alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels among HIV-seropositive patients receiving antiretroviral therapy.
Methods: A comparative study was conducted involving 59 HIV-seropositive participants and 31 control participants. Serum ALP, AST, and ALT levels were evaluated before and after ART among the HIV-seropositive participants and compared with those of the control group. Descriptive statistics were used to summarize the results. Paired-samples and independent-samples t-tests were used to assess differences in mean enzyme levels, with statistical significance set at p < 0.05.
Results: Among the HIV-seropositive participants, mean ALP decreased from 81.42 ± 50.22 to 49.15 ± 29.32 U/L, AST decreased from 13.34 ± 12.93 to 10.58 ± 7.33 U/L, and ALT decreased from 11.98 ± 6.96 to 9.22 ± 4.32 U/L after ART. The paired-samples t-test showed statistically significant reductions in ALP (t = −6.880, p < 0.001) and ALT (t = −2.939, p = 0.005), but not in AST (t = −1.469, p = 0.147). Compared with controls, pre-ART ALP levels were significantly higher among HIV-seropositive participants (t = 2.657, p = 0.009). However, differences in AST (p = 0.128) and ALT (p = 0.184) were not statistically significant.
Conclusion: The study found significant differences in ALP levels between HIV-seropositive participants before ART and controls, as well as significant reductions in ALP and ALT following ART. These findings demonstrate changes in selected liver-associated biochemical markers among the study participants. However, the observed changes do not independently establish that ART caused the reductions or confirm improvement in overall liver function.
Keywords: HIV, antiretroviral therapy, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, liver enzymes